Nasus Pharma Ltd. (NSRX) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Nasus Pharma Ltd. (NSRX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $26.0M, listed on AMEX, employing roughly 2 people, carrying a beta of 3.89 to the broader market. Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Led by Dan Teleman, public since 2025-08-13.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for NSRX as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.